CDCES Pathophysiology of Diabetes 1 — Questions and Answers
Question 1: Which autoantibody is most specific for type 1 diabetes and is present in approximately 70-80% of newly diagnosed patients?
- Anti-insulin antibody (IAA)
- Glutamic acid decarboxylase antibody (GADA) (Correct answer)
- Islet cell antibody (ICA)
- Zinc transporter 8 antibody (ZnT8A)
Correct answer: Glutamic acid decarboxylase antibody (GADA)
GADA (anti-GAD65) is the most commonly detected and most specific autoantibody in type 1 diabetes, present in 70-80% of new-onset patients.
Type 1 diabetes is an autoimmune disease where T-cells destroy pancreatic beta cells. Multiple autoantibodies can precede clinical diagnosis: GADA (anti-glutamic acid decarboxylase) is found in approximately 70-80% of new-onset T1D patients and is the most widely used screening marker. IAA is more prevalent in young children. ICA was the first discovered but is less specific. ZnT8A is useful when other antibodies are negative. The presence of two or more autoantibodies predicts progression to clinical T1D. The CDCES distinguishes T1D from T2D pathophysiology for appropriate education planning.
Question 2: In type 2 diabetes, which physiological defect is considered the PRIMARY initiating mechanism in the majority of patients?
- Absolute insulin deficiency due to beta-cell destruction
- Peripheral insulin resistance with compensatory hyperinsulinemia (Correct answer)
- Glucagon deficiency causing fasting hypoglycemia
- Excessive GLP-1 secretion stimulating excess insulin
Correct answer: Peripheral insulin resistance with compensatory hyperinsulinemia
Type 2 diabetes is initiated by peripheral insulin resistance (primarily in muscle, liver, and adipose tissue) with compensatory beta-cell hyperinsulinemia that eventually fails.
The pathophysiology of type 2 diabetes involves a complex interplay of defects, but peripheral insulin resistance -- particularly in skeletal muscle, hepatic tissue, and adipose tissue -- is the primary initiating mechanism. Initially, pancreatic beta cells compensate by producing more insulin (hyperinsulinemia). Over time, beta-cell exhaustion occurs, insulin secretion declines, and hyperglycemia develops. The ominous octet (DeFronzo) describes 8 contributing defects including decreased incretin effect, increased glucagon secretion, increased renal glucose reabsorption, and neurotransmitter dysfunction.
Question 3: The incretin effect refers to which physiological phenomenon?
- Glucagon suppression by dietary fat ingestion
- Enhanced insulin secretion in response to oral glucose compared to IV glucose due to gut hormones (Correct answer)
- Delayed gastric emptying caused by high-fiber foods
- Increased insulin sensitivity from regular aerobic exercise
Correct answer: Enhanced insulin secretion in response to oral glucose compared to IV glucose due to gut hormones
The incretin effect is the amplification of postprandial insulin secretion triggered by gut hormones (GLP-1, GIP) released after oral glucose ingestion, beyond what IV glucose alone would stimulate.
When glucose is ingested orally, intestinal L-cells and K-cells release GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), respectively. These incretins potentiate glucose-stimulated insulin secretion, accounting for up to 50-70% of postprandial insulin response in healthy individuals. In type 2 diabetes, the incretin effect is significantly diminished (due to impaired GLP-1 response and GIP resistance), contributing to postprandial hyperglycemia. GLP-1 receptor agonists and DPP-4 inhibitors pharmacologically exploit the incretin pathway.
Question 4: Which statement about gestational diabetes mellitus (GDM) pathophysiology is correct?
- GDM is caused by destruction of pancreatic beta cells by placental autoantibodies
- GDM results from placental hormones increasing insulin resistance, unmasking inadequate beta-cell reserve (Correct answer)
- GDM is always permanent and progresses to type 1 diabetes postpartum
- GDM is solely caused by excessive weight gain during pregnancy
Correct answer: GDM results from placental hormones increasing insulin resistance, unmasking inadequate beta-cell reserve
Placental hormones (hPL, progesterone, cortisol) progressively increase insulin resistance during pregnancy, and women with insufficient beta-cell reserve cannot compensate, resulting in GDM.
During pregnancy, placental hormones -- especially human placental lactogen (hPL), progesterone, estrogen, and cortisol -- progressively increase insulin resistance, peaking in the third trimester. Most pregnant women compensate with 2-3 times increased insulin secretion. Women who develop GDM have an underlying beta-cell secretory limitation that is unmasked by this physiological insulin resistance. GDM is not autoimmune in etiology. It typically resolves postpartum but confers a 7-fold increased lifetime risk of type 2 diabetes. The CDCES addresses postpartum diabetes prevention for all women with GDM history.
Question 5: Diabetic ketoacidosis (DKA) occurs primarily because of which underlying pathophysiological mechanism?
- Excess dietary fat intake causing ketone accumulation
- Absolute or near-absolute insulin deficiency combined with counter-regulatory hormone excess driving unregulated lipolysis and ketogenesis (Correct answer)
- Impaired renal excretion of glucose causing toxic glucose accumulation
- Excessive insulin causing hypoglycemia that triggers compensatory ketone production
Correct answer: Absolute or near-absolute insulin deficiency combined with counter-regulatory hormone excess driving unregulated lipolysis and ketogenesis
DKA is caused by absolute or severe insulin deficiency plus glucagon/cortisol/catecholamine excess, which drives unregulated lipolysis, fatty acid release, and hepatic ketogenesis.
In DKA, absolute or severe insulin deficiency removes the primary inhibitor of lipolysis; adipose tissue releases massive amounts of free fatty acids into circulation. Counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) amplify lipolysis and stimulate hepatic fatty acid oxidation to ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone). The resulting ketoacidemia lowers blood pH (metabolic acidosis). Simultaneously, glucagon stimulates hepatic glucose output, worsening hyperglycemia. The CDCES teaches DKA prevention through sick-day rules, ketone monitoring protocols, and never-stop-insulin education.
Question 6: Which mechanism explains how chronic hyperglycemia causes microvascular complications such as diabetic retinopathy?
- Hyperglycemia directly destroys the optic nerve through osmotic pressure
- Advanced glycation end-products (AGEs), polyol pathway activation, and oxidative stress damage endothelial cells (Correct answer)
- Excess insulin causes vasoconstriction that reduces retinal blood flow
- High glucose levels increase HDL cholesterol, depositing in retinal vessels
Correct answer: Advanced glycation end-products (AGEs), polyol pathway activation, and oxidative stress damage endothelial cells
Chronic hyperglycemia activates multiple pathways -- AGE formation, polyol accumulation, PKC activation, oxidative stress -- that damage vascular endothelial cells and basement membranes, leading to microvascular complications.
The unifying hypothesis of diabetic microvascular complications involves four major hyperglycemia-activated pathways: (1) AGE formation (cross-links proteins, stiffens vessel walls), (2) polyol pathway activation (sorbitol accumulates, depletes NADPH and glutathione), (3) PKC (protein kinase C) activation (increases vascular permeability and inflammation), and (4) hexosamine pathway flux (impairs insulin signaling). All converge on reactive oxygen species production, endothelial dysfunction, and basement membrane thickening. These mechanisms affect retinal, renal, and peripheral nerve vasculature. The CDCES uses this knowledge to motivate patients about glucose control and early screening.
CDCES Pathophysiology of Diabetes 1
Which autoantibody is most specific for type 1 diabetes and is present in approximately 70-80% of newly diagnosed patients?